Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 116
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04715191 | Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | ||
| NCT00368082 | Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) | ||
| NCT00889954 | Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy | ||
| NCT00058812 | Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts | ||
| NCT00058799 | Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine | ||
| NCT01604031 | Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide | ||
| NCT00056966 | Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases | ||
| NCT03192462 | TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer | ||
| NCT01109095 | CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM | ||
| NCT03774654 | CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) | ||
| NCT02905188 | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) | ||
| NCT01822652 | 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN | ||
| NCT01555892 | Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE | ||
| NCT00840853 | Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT | ||
| NCT00458679 | Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells | ||
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | ||
| NCT03635632 | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | ||
| NCT00609219 | T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC | ||
| NCT00062868 | LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma | ||
| NCT01494103 | Administration of Donor T Cells With the Caspase-9 Suicide Gene | ||
| NCT00902044 | Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma | ||
| NCT01713439 | Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL | ||
| NCT05236764 | Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion | ||
| NCT03768310 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) | ||
| NCT01192464 | EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma | ||
| NCT01945619 | Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH) | ||
| NCT02932956 | Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) | ||
| NCT06176690 | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas | ||
| NCT06251544 | TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer | ||
| NCT03596086 | HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | ||
| NCT01205334 | Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme | ||
| NCT06598332 | 5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD) | ||
| NCT04099797 | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | ||
| NCT01070797 | Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) | ||
| NCT00062855 | Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma | ||
| NCT00058591 | Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs) | ||
| NCT04345601 | Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) | ||
| NCT01316146 | Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) | ||
| NCT02442297 | T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors | ||
| NCT00368355 | T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts | ||
| NCT00058604 | Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). | ||
| NCT01189786 | Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection | ||
| NCT01333046 | Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL | ||
| NCT03762291 | Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine | ||
| NCT02050347 | Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) | ||
| NCT01460901 | Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma | ||
| NCT07211737 | NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma | ||
| NCT00048412 | Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H | ||
| NCT00057005 | Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation | ||
| NCT00515957 | Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) |
